Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.59 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.57 |
| ▸ | GNPAT | O15228 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.53 |
| ▸ | CPA1 | P15085 | 2/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30799461 | 0.95 | MME (0.54) | MMECTRB1GNPATALDH1A1THRB | |
| SCHEMBL29576197 | 0.94 | MME (0.57) | MMECTRB1ALDH1A1THRBCYP2C9 | |
| SCHEMBL29531699 | 0.94 | MME (0.57) | MMECTRB1ALDH1A1THRBCYP2C9 | |
| SCHEMBL29702065 | 0.93 | MME (0.61) | MMECTRB1GNPATACECPA1 | |
| SCHEMBL29367272 | 0.92 | MME (0.51) | MMECTRB1GNPATALDH1A1THRB | |
| SCHEMBL30799258 | 0.90 | CTRB1 (0.50) | MMECTRB1GNPATALDH1A1THRB | |
| SCHEMBL31441080 | 0.90 | MME (0.58) | MMEACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL893240 | 0.90 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL28743188 | 0.90 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL893241 | 0.90 | MME (0.65) | MMECTRB1ACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376151-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376151-A1 | STAPLED PEPTIDES AND METHODS THEREOF | VIP, IAPP, GLP1R | MME 438/4885CTRB1 1526/4885GNPAT 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.